Myriad Genetics enters collaboration with the VA
Assurex Health, a wholly-owned subsidiary of Myriad Genetics, announced that the Department of Veterans Affairs, or VA, recently initiated a national, multi-center trial to evaluate the company's GeneSight test to help improve health outcomes for veterans diagnosed with major depressive disorder, or MDD. Approximately 20% of the 2.6M veterans who deployed to Iraq or Afghanistan returned with MDD or a related mental health condition, and tragically suicide rates for veterans are twice that of the United States population. The study titled, PRIME Care, or PRecision Medicine In MEntal Health Care, is a randomized clinical trial to determine how providers use and patients respond to GeneSight-guided therapy. The VA has committed $12M to fund the study that will enroll 2,000 patients with MDD and include 250 healthcare providers at 21 VA medical centers. The study is expected to complete in 2021.